Strategies to inhibit HMGB1, such as the use of neutralizing antibodies or small molecules that interfere with its release or activity, could potentially improve outcomes in patients with sepsis by reducing the hypercoagulable state and associated organ damage. The gene discussed is HMGB1; the disease is Sepsis.